Literature DB >> 11564649

Distinction between relaxations induced via prostanoid EP(4) and IP(1) receptors in pig and rabbit blood vessels.

R L Jones1, K Chan.   

Abstract

1. Our study shows that the prostacyclin analogues AFP-07 and cicaprost are moderately potent agonists for prostanoid EP(4) receptors, in addition to being highly potent IP(1) receptor agonists. Both activities were demonstrated on piglet and rabbit saphenous veins, which are established EP(4) preparations. 2. On piglet saphenous vein, PGE(2) was 6.1, 24, 96, 138, 168 and 285 times respectively more potent than AFP-07, cicaprost, PGI(2), iloprost, carbacyclin and TEI-9063 in causing relaxation. Another prostacyclin analogue taprostene did not induce maximum relaxation (21 - 74%), and did not oppose the action of PGE(2). The EP(4) receptor antagonist AH 23848 (30 microM) blocked relaxant responses to PGE(2) (dose ratio=8.6+/-1.3, s.e.mean) to a greater extent than cicaprost (4.9+/-0.7) and AFP-07 (3.8+/-0.8), had variable effects on TEI-9063-induced relaxation (3.7+/-1.5), and had no effect on taprostene responses (<2.0). 3. On rabbit saphenous vein, AH 23848 blocked the relaxant actions of PGE(2), AFP-07, cicaprost, iloprost and carbacyclin to similar extents. 4. AFP-07, cicaprost and TEI-9063 showed high IP(1) relaxant potency on piglet carotid artery, rabbit mesenteric artery and guinea-pig aorta, with AFP-07 confirmed as the most potent IP(1) agonist reported to date. AH 23848 did not block cicaprost-induced relaxation of piglet carotid artery. EP(3) contractile systems in these preparations can confound IP(1) agonist potency estimations. 5. Caution is urged when using AFP-07 and cicaprost to characterize IP(1) receptors in the presence of EP(4) receptors. Taprostene may be a lead to a highly selective IP(1) receptor agonist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564649      PMCID: PMC1572952          DOI: 10.1038/sj.bjp.0704252

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

Authors:  M Abramovitz; M Adam; Y Boie; M Carrière; D Denis; C Godbout; S Lamontagne; C Rochette; N Sawyer; N M Tremblay; M Belley; M Gallant; C Dufresne; Y Gareau; R Ruel; H Juteau; M Labelle; N Ouimet; K M Metters
Journal:  Biochim Biophys Acta       Date:  2000-01-17

2.  Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324.

Authors:  R L Jones; Y M Qian; K M Chan; A P Yim
Journal:  Br J Pharmacol       Date:  1998-11       Impact factor: 8.739

3.  TEI-9063, a stable and highly specific prostacyclin analogue for the prostacyclin receptor in mastocytoma P-815 cells.

Authors:  M Negishi; H Hashimoto; K Yatsunami; S Kurozumi; A Ichikawa
Journal:  Prostaglandins       Date:  1991-09

4.  AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.

Authors:  R T Brittain; L Boutal; M C Carter; R A Coleman; E W Collington; H P Geisow; P Hallett; E J Hornby; P P Humphrey; D Jack
Journal:  Circulation       Date:  1985-12       Impact factor: 29.690

5.  Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues.

Authors:  Y J Dong; R L Jones; N H Wilson
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

6.  New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors.

Authors:  R A Coleman; I Kennedy; R L Sheldrick
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1987

7.  In vitro studies with the stabilized epoprostenol analogue taprostene. Effect on platelets and erythrocytes.

Authors:  G Michel; U Seipp
Journal:  Arzneimittelforschung       Date:  1990-07

8.  Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979.

Authors:  P J Gardiner
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

9.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

Authors:  S Bunting; R Gryglewski; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1976-12

10.  GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.

Authors:  P Lumley; B P White; P P Humphrey
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

View more
  6 in total

1.  Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists.

Authors:  Winnie W C Shum; Geng-Yun Le; Robert L Jones; Alison M Gurney; Yasuharu Sasaki
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

2.  Apolipoprotein E favours the blunting by high-fat diet of prostacyclin receptor activation in the mouse aorta.

Authors:  Yanhua Cheng; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2018-07-22       Impact factor: 8.739

3.  Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.

Authors:  R L Jones; H Wise; R Clark; R L Whiting; K R Bley
Journal:  Br J Pharmacol       Date:  2006-07-31       Impact factor: 8.739

Review 4.  Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.

Authors:  Batoule H Majed; Raouf A Khalil
Journal:  Pharmacol Rev       Date:  2012-06-07       Impact factor: 25.468

Review 5.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

6.  Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes.

Authors:  Bainian Chen; Qing Zhao; Rui Ni; Futian Tang; Limei Shan; Inga Cepinskas; Gediminas Cepinskas; Wang Wang; Peter W Schiller; Tianqing Peng
Journal:  Cardiovasc Diabetol       Date:  2014-05-03       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.